A methyl salicylate transdermal patch and a topical with an ingredient made available nonprescription in the US in 2020 are among the first OTC nonsteroidal anti-inflammatory drugs re-labeled to more strongly warn against use during pregnancy or while nursing.
The Food and Drug Administration’s Center for Drug Evaluation and Research since late October has sent approvals to firms which...





